Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma-Reference-Cited by-同舟云学术

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Published:2019-01-08 Issue:2 Volume:60 Page:511-514
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Amsler Isabel G.¹,Jeker Barbara¹,Mansouri Taleghani Behrouz²,Bacher Ulrike²,Betticher Daniel³,Egger Thomas⁴,Zander Thilo⁵,Luethi Jean-Marc⁶,Novak Urban¹,Pabst Thomas¹

Affiliation:

1. Department of Medical Oncology, Bern University Hospital, Bern, Switzerland;

2. Department of Hematology, University Hospital, Bern, Switzerland;

3. Department of Oncology, Kantonsspital, Fribourg, Switzerland;

4. Department of Oncology, Kantonsspital, Solothurn, Switzerland;

5. Department of Oncology, Kantonsspital, Lucerne, Switzerland;

6. Department of Medical Oncology, Bern University Hospital, Regionalspital, Thun, Switzerland

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1473577

Reference13 articles.

1. IMWG consensus on maintenance therapy in multiple myeloma

2. Posttransplant maintenance therapy in multiple myeloma: the changing landscape

3. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

4. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

5. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma;New England Journal of Medicine;2022-07-14

2. Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?;Hemato;2022-06-23

3. A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022;Expert Review of Anticancer Therapy;2022-05-03

4. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial;Bone Marrow Transplantation;2022-04-20

5. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM);Blood Cancer Journal;2021-09